Study of a new medical device to treat brain aneurysms

	-	NA STATE OF THE ST
Submission date 14/01/2020	Recruitment status No longer recruiting	[X] Prospectively registered
		☐ Protocol
Registration date 16/01/2020	Overall study status Ongoing	Statistical analysis plan
		Results
Last Edited 04/06/2024	Condition category Circulatory System	Individual participant data
		Record updated in last year
Plain English summ Background and stu The study aims to e aneurysms.	udy aims	effectiveness of a new device to treat brain
Who can participate Patients with intrac		
What does the stud The study involves		nally invasive device and a follow-up visit
Potential benefits i	_	participating? ng. Like in any surgical intervention, there are possible presented to subjects before enrollment.
Where is the study The General Hospit	run from? al of Fortaleza (Brazil)	
When is the study s January 2020 to De		it expected to run for?
Who is funding the EndoStream Medica	-	
Who is the main contact?		

Contact information

Danel Mayer, CEO

danel@endostream.com

Type(s)
Public

Contact name

Mr Danel Mayer

Contact details

12 Haílan St PO Box 265 Or Akiva Israel 3065201 +972 (0)4 842 4810 danel@endostream.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CLD219

Study information

Scientific Title

Nautilus endovascular device for wide neck cerebral aneurysm embolization study

Acronym

NEW

Study objectives

Safety and effectiveness of the investigational device.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 16/11/2019, Hospital Geral de Fortaleza/SUS (Government Unified Health System) (Rua Avila Goulart, n° 900, Fortaleza, 60.155-290, Brazil; +55 (85) 3101-7078; cephgf.ce@gmail.com), ref: 3.708.271

Approved 16/11/2019, Hospital Geral de Fortaleza Ethics Committee (Comitê de Ética do Hospital Geral de Fortaleza,

Rua Avila Goulart, n° 900 - Fortaleza - CE - Brazil, 60.155-290; Tel: +55 (85)3101-7078; Email: cephqf.ce@gmail.com), approval number: 3.708.271, EC ID number: 23797919.1.0000.5040

Study design

Interventional single-arm study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Cerebral aneurysm

Interventions

Patients will undergo a single intervention with the Nautilus Endovascular Device followed by treatment follow up at 6 months.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Nautilus Endovascular Device

Primary outcome measure

Death or stroke in treated vascular territory measured using the NIH stroke scale at intervention and at 6 months follow-up

Secondary outcome measures

Rate of stable, successful aneurysm occlusion measured using the Raymond Roy Occlusion Classification at intervention and at 6 months follow-up

Overall study start date

01/01/2020

Completion date

01/12/2025

Eligibility

Key inclusion criteria

Patients who present with intracranial aneurysm

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

50

Key exclusion criteria

Unstable neurological deficit

Date of first enrolment

01/09/2022

Date of final enrolment

30/06/2025

Locations

Countries of recruitment

Brazil

Israel

Study participating centre Hospital Geral de Fortaleza

R. Ávila Goularte, 900 - Papicu Fortaleza Brazil 60150-160

Sponsor information

Organisation

EndoStream Medical Ltd

Sponsor details

12 Haílan St. PO Box 265 Or Akiva Israel 3065201 +972 (0)4 842 4810 danel@endostream.com

Sponsor type

Industry

Website

endostream.com

Funder(s)

Funder type

Industry

Funder Name

EndoStream Medical Ltd

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal. No additional documents are available at this time.

Intention to publish date

01/12/2026

Individual participant data (IPD) sharing plan

The data will be held by the Principal Investigator of the study until the product becomes commercially available.

IPD sharing plan summary

Not expected to be made available